Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study

Lene Boesby; Thomas Elung-Jensen; Tobias Wirenfeldt Klausen; Svend Strandgaard; Anne-Lise Kamper

doi:10.1371/journal.pone.0026904

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study

Lene Boesby, Thomas Elung-Jensen, Tobias Wirenfeldt Klausen, Svend Strandgaard, Anne-Lise Kamper

Nyresygdomme

47 Citationer (Scopus)

Abstract

Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD). The aldosterone antagonist spironolactone has an antiproteinuric effect, but its use is limited by side effects. The present study evaluated the short-term antiproteinuric effect and safety of the selective aldosterone antagonist eplerenone in non-diabetic CKD.

Originalsprog	Engelsk
Tidsskrift	P L o S One
Vol/bind	6
Udgave nummer	11
Sider (fra-til)	e26904
ISSN	1932-6203
DOI	https://doi.org/10.1371/journal.pone.0026904
Status	Udgivet - 2011

Adgang til dokumentet

10.1371/journal.pone.0026904

Citationsformater

@article{eb3c8a0f92e94a8ebd97cddfa31c8b3b,

title = "Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study",

abstract = "Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD). The aldosterone antagonist spironolactone has an antiproteinuric effect, but its use is limited by side effects. The present study evaluated the short-term antiproteinuric effect and safety of the selective aldosterone antagonist eplerenone in non-diabetic CKD.",

author = "Lene Boesby and Thomas Elung-Jensen and Klausen, {Tobias Wirenfeldt} and Svend Strandgaard and Anne-Lise Kamper",

year = "2011",

doi = "10.1371/journal.pone.0026904",

language = "English",

volume = "6",

pages = "e26904",

journal = "P L o S One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "11",

}

TY - JOUR

T1 - Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study

AU - Boesby, Lene

AU - Elung-Jensen, Thomas

AU - Klausen, Tobias Wirenfeldt

AU - Strandgaard, Svend

AU - Kamper, Anne-Lise

PY - 2011

Y1 - 2011

N2 - Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD). The aldosterone antagonist spironolactone has an antiproteinuric effect, but its use is limited by side effects. The present study evaluated the short-term antiproteinuric effect and safety of the selective aldosterone antagonist eplerenone in non-diabetic CKD.

AB - Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD). The aldosterone antagonist spironolactone has an antiproteinuric effect, but its use is limited by side effects. The present study evaluated the short-term antiproteinuric effect and safety of the selective aldosterone antagonist eplerenone in non-diabetic CKD.

U2 - 10.1371/journal.pone.0026904

DO - 10.1371/journal.pone.0026904

M3 - Journal article

C2 - 22073219

SN - 1932-6203

VL - 6

SP - e26904

JO - P L o S One

JF - P L o S One

IS - 11

ER -

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater